EIF2AK2 and Cachexia: The relevance of this process to cancer cachexia is demonstrated by the ability of a PKR-inhibitor to abate skeletal muscle atrophy in a mouse model of cachexia by attenuating UPS-dependent proteolysis and increasing protein synthesis [88].